Navigation Links
Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
Date:10/30/2007

ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced top-line results from the Company's Proof- of-Concept Phase II clinical trial evaluating VSF-173 in a clinical model of excessive sleepiness.

This Phase II study examined the effects of VSF-173 on a model of excessive sleepiness among 55 healthy volunteers treated with 3 doses of VSF-173 administered at 50 mg, 100 mg and 200 mg and placebo administered at 25 mg, 50 mg and 100 mg at the usual bedtime and at four hours after the first dose. In this model, the effect of the compound was evaluated with a series of six Maintenance of Wakefulness Tests (MWT) given two hours apart starting one hour after the first dose. The effect of the drug was also evaluated on the scheduled daytime recovery sleep following the night time and morning evaluations.

On the primary endpoint which evaluated the effect of the compound on the first four series of MWT tests, VSF-173 demonstrated improvements over placebo. The mean MWT sleep onset scores for the 50 mg, 100 mg and 200 mg, and placebo groups were 10.3, 12.9, 10.6 and 9.2 minutes, respectively. While the pair-wise analysis did not reach statistical significance, this magnitude of effect, ranging from 1.1 to 3.7 minutes, is generally similar to that observed with modafinil in the treatment of patients with narcolepsy.

In a subset of 37 subjects with no observed impairment in pre-dose daytime wakefulness (MWT cutoff equal to 30 minutes), the mean of all six MWT scores for the 50 mg, 100 mg and 200 mg groups show
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... ... Isabel Healthcare announced today that it will donate the use of the ... Free Health Clinic. The Isabel diagnosis decision support solution will be used ... their perspective while working up their patients. Isabel will also provide contextual links ...
(Date:6/30/2015)... ... June 30, 2015 , ... New Xarelto lawsuit ... the use of new forms, according to attorneys handling Xarelto lawsuits ... Short Form Complaint, “provide guidance” for plaintiffs’ attorneys in filing new claims, according ...
(Date:6/30/2015)... Petersburg, FL (PRWEB) , ... June 30, 2015 , ... Skin Brushing (also known as ... helpful to keep skin optimal and beautiful as it is more exposed to the elements. ... It can:, , Exfoliate the dead cells and toxins on skin's ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... 2015 amidst bright skies and inspirational words. , The independent, coeducational, special ... from the Glenholme building to the school’s Center for the Arts. Along the ...
(Date:6/30/2015)... ... June 30, 2015 , ... Intellitec Solutions has announced they will be ... CRM. With the enhanced changes and new procedures involved with updating the cloud version ... a look at the new user interface and what it will mean for end ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare Donates Differential Diagnosis Decision Support Tool to That Neighborhood Foundation 2Health News:Isabel Healthcare Donates Differential Diagnosis Decision Support Tool to That Neighborhood Foundation 3Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:Back in Stock: Keep Skin and Lymphatic System Healthy with Dry Skin Brushes from Sublime Beauty® 2Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Intellitec Solutions to Host Microsoft CRM 2015 Update Webinar 2
... of exposure set by CDC need to be lowered, experts ... blood lead levels well below those considered safe are still ... researchers report. , Currently, the maximum safe blood level of ... set by the U.S. Centers for Disease Control and Prevention ...
... The online CURE ... of its readers living with cancer to uncover challenges facing patients today and better identify ... East Hanover, ... three patients with rare cancers - twice the number as those with more common cancers ...
... , , , ... with prescription drug coverage are more satisfied with their pharmacy ... those with wholly private insurance, according to the J.D. Power ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) , , ...
... Calif., Sept. 17 DURECT Corporation (Nasdaq: DRRX ) ... healthcare conferences. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) ... Hogan, Chief Financial Officer, will present at the UBS Global Life ... a.m. Eastern Time. A live audio webcast of the presentation ...
... NEOG ) announces the following Webcast: , , , ... When: Thursday, September 24, 2009 @ 11:00 ET, Where: ... Internet -- Simply log on to the web at the, ... of Neogen Corporation, +1-800-234-5333., , , If you are unable ...
... , , , ... to expand its brand, Nutrisystem Inc., (Nasdaq: NTRI ), is ... Diet in Japan. Capitalizing on the success of Nutrisystem branded ... Foods will begin to sell Nutrisystem J Diet in Japan on October ...
Cached Medicine News:Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 2Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 3Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 2Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 3Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 4Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 5Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 6Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 7Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 2Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 3
(Date:6/30/2015)... June 30, 2015  Today, the National Mobility Equipment ... 2015 National Mobility Awareness Month Local Heroes Contest on ... online entries that received 1.3 million votes. The sponsors ... Toyota Mobility , and Valley Honda Dealers ... and Vantage Mobility International (VMI) and ...
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
Breaking Medicine Technology:NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3